Skip to content

Integra LifeSciences IART Specialty Surgery — Total Revenues

Other segment segments

Tissue Reconstruction
$108.78M

Similar metrics at other companies

Bausch + Lomb logo
BLCOSurgical — Total revenues
$228M+6.5%
Radian Group logo
RDNSpecialty Segment Operating — Revenue
$182.58M
LKQ logo
LKQSpecialty — Revenue
$409M+3.8%
CNA Financial logo
CNASpecialty — Operating Revenues
$1.37B-0.7%
Artivion logo
AORTMedical devices — Total revenues
$91.44M+16.0%
Bausch + Lomb logo
BLCODevices — Total revenues
$480M+7.1%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's specialty surgery — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's specialty surgery — total revenues?
Integra LifeSciences (IART) reported specialty surgery — total revenues of $283.14M in Q1 2026.
What does specialty surgery — total revenues mean?
This metric represents the total gross revenue generated by the Specialty Surgery business segment from the sale of medical devices and related services. It serves as a primary indicator of the segment's market demand and top-line growth performance within the broader medical technology portfolio.